Abstract:Background The gut microbiota, a pivotal regulator in colorectal cancer (CRC) development, is profoundly involved in drug metabolism. This study aims to decipher the role of the gut microbiota in aspirin-mediated chemoprevention of CRC in mice. Methods Two models, azoxymethane (AOM, 10 mg/kg) and dextran sulfate sodium (DSS, 2.0%) induced CRC and APCmin/+ induced CRC, were used in this study. Mice were orally administered aspirin (400 mg/L) with or without periodical antibiotics cocktail (0.1 g/L of vancomycin, 0.2 g/L of ampicillin, metronidazole and neomycin). AOM/DSS-treated germ-free mice and conventionally reared germ-free mice (conventionalized mice) were used for validation. Aspirin concentration was estimated by ultra-high performance liquid chromatography (UHPLC). Aspirin-degrading microbes were identified by UHPLC and16S rRNA gene sequencing. Results The tumor number and load were significantly reduced after aspirin treatment in antibiotics-treated mice in both AOM/DSS-treated and APCmin/+ models, but not significantly changed in non-antibiotics-treated mice. Consistently, aspirin-treated germ-free mice exhibited significantly less tumor number and load compared to those not receiving aspirin, which was not seen in conventionalized mice, suggesting that gut microbiota impairs the chemopreventive efficacy of aspirin on CRC. UHPLC analysis revealed that plasma levels of aspirin were significantly higher in microbiota-depleted mice compared to microbiota-intact mice, indicating that gut microbiota limits aspirin bioavailability. Co-incubation of aspirin-containing medium and bacteria showed that aspirin levels in medium were significantly reduced when incubated with the fecal commensal bacteria from microbiota-intact mice compared to those from microbiota-depleted mice. Screening 1,093 bacterial colonies isolated from the feces of microbiota-intact mice revealed that Lysinibacillus sphaericus significantly reduced the aspirin levels in aspirin-containing medium. Moreover, the germ-free mice monocolonized with Lysinibacillus sphaericus showed significantly lower plasma aspirin levels post aspirin administration relative to the intact germ-free mice, confirming a role of this bacterium in reducing aspirin bioavailability. Conclusions Gut microbiota modulates the chemopreventive efficacy of aspirin on CRC through impact on aspirin bioavailability in mice. Lysinibacillus sphaericus may play a critical role in aspirin degradation in the gut.

Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq

DNA methylome and transcriptome alterations and cancer prevention by curcumin in colitis-accelerated colon cancer in mice

Aspirin Prevent Colorectal Cancer Via <i>enterococcus Cecorum</i> -TIGIT <sup>+</sup>treg Cell Axis

The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice

Curcumin Suppresses Colorectal Tumorigenesis Via the Wnt/β-catenin Signaling Pathway by Downregulating Axin2.

Combining gamma-tocopherol and aspirin synergistically suppresses colitis-associated colon tumorigenesis and modulates the gut microbiota in mice, and inhibits the growth of human colon cancer cells

Post-transcriptional Gene Regulation in Colitis Associated Cancer

Chemopreventive Effects of Polysaccharides and Flavonoids from Okra Flowers in Azomethane/Dextran Sulfate Sodium-Induced Murine Colitis-Associated Cancer

Could Aspirin and Diets High in Fiber Act Synergistically to Reduce the Risk of Colon Cancer in Humans?

Cancer-protective effect of a synbiotic combination between Lactobacillus gasseri 505 and a Cudrania tricuspidata leaf extract on colitis-associated colorectal cancer

Effects of aspirin on tumor cells apoptosis in a murine model of colitis-associated colorectal cancer

Aspirin prevents colorectal cancer by regulating the abundance of Enterococcus cecorum and TIGIT+Treg cells

Suppression of colorectal cancer growth: Interplay between curcumin and metformin through DMT1 downregulation and ROS‐mediated pathways

IDDF2019-ABS-0188 Gut Microbiota Modulates the Chemopreventive Efficacy of Aspirin on Colorectal Cancer Through Impact on Aspirin Bioavailability

Altered gut metabolites and metabolic reprogramming involved in the pathogenesis of colitis-associated colorectal cancer and the transition of colon "inflammation to cancer"

Curcumin inhibits colorectal cancer development by blocking the YAP/TAZ signaling axis

Uncovering the Anticancer Mechanism of Compound Sophorae Decoction against Ulcerative Colitis-Related Colorectal Cancer in Mice

Aspirin inhibits prostaglandins to prevents colon tumor formation via down-regulating Wnt production

Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development.

Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6–STAT3 signaling pathway

Genistein–Aspirin Combination Exerts Cytotoxic and Anti-Migratory Effects in Human Colorectal Cancer Cells